Stemline Therapeutics Inc (STML.OQ)

STML.OQ on NASDAQ Stock Exchange Capital Market

11.54USD
28 Jul 2014
Price Change (% chg)

$-0.42 (-3.51%)
Prev Close
$11.96
Open
$12.00
Day's High
$12.05
Day's Low
$11.22
Volume
28,695
Avg. Vol
43,039
52-wk High
$47.18
52-wk Low
$10.69

STML.OQ

Chart for STML.OQ

About

Stemline Therapeutics, Inc. (Stemline) is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics that target both cancer stem cells (CSCs) and tumor bulk. The Company is developing two clinical-stage product candidates, SL-401 and SL-701, for which it holds... (more)

Overall

Beta: --
Market Cap (Mil.): $152.84
Shares Outstanding (Mil.): 13.24
Dividend: --
Yield (%): --

Financials

  STML.OQ Industry Sector
P/E (TTM): -- 103.84 36.07
EPS (TTM): -2.30 -- --
ROI: -54.76 -0.24 18.18
ROE: -55.39 -1.24 19.05
Search Stocks

Competitors

  Price Change
Astellas Pharma Inc (4503.T) ¥1,422 +8.00
Eisai Co., Ltd (4523.T) ¥4,382 +53.00
Sumitomo Dainippon Pharma Co Ltd (4506.T) ¥1,241 +9.00
Pfizer Inc. (PFE.N) $30.10 -0.09
Novartis AG (NOVN.VX) CHF80.00 +0.60
Merck & Co., Inc. (MRK.N) $57.97 -0.18
Roche Holding Ltd. (ROG.VX) CHF266.80 +1.30
Sanofi SA (SASY.PA) €77.24 +0.91
GlaxoSmithKline plc (GSK.L) 1,431.00p +16.50
Amgen, Inc. (AMGN.OQ) $122.65 -0.19

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Ford Investor Services, Inc.
$12.00
Provider: GlobalData
$250.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks